Balanced Propofol Sedation Versus Propofol Alone Sedation in Therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Soon Chun Hyang University
ClinicalTrials.gov Identifier:
NCT01321047
First received: March 22, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

Based on previous results, the investigators considered that sedation quality, complications, and procedure outcomes may not be different, however, propofol alone titration may have a fast recovery time than BPS and cost-effectiveness than balanced propofol sedation (BPS). In present study, the investigators therefore evaluate the time and sedation quality of patient recovery, cost-effectiveness, complication, and procedure outcomes between propofol alone and BPS in therapeutic endoscopic retrograde cholangiopancreatography (ERCP).


Condition Intervention Phase
Conscious Sedation Failure During Procedure
Drug: Propofol
Drug: BPS
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation

Resource links provided by NLM:


Further study details as provided by Soon Chun Hyang University:

Primary Outcome Measures:
  • Recovery time and cost-effectiveness [ Time Frame: SIX MONTH ] [ Designated as safety issue: Yes ]
    Following therapeutic ERCP,full recovery time scoring by Aldrete scoring system and cost measured.


Secondary Outcome Measures:
  • Sedation efficacy, procedure-related outcomes, and complications. [ Time Frame: SIX MONTH ] [ Designated as safety issue: Yes ]

    Sedation efficacy parameters was defined as follows; Onset of effective sedation, Patient cooperation (endoscopist, observer-nurse), recovery time, and Patient tolerance (rated by the patients 4hr after procedure).

    Quality of procedure was assessed by procedure outcomes and procedure related complications.



Estimated Enrollment: 204
Study Start Date: April 2011
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Propofol group
the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
Drug: Propofol
propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
Other Name: A GROUP
Active Comparator: BPS group
the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
Drug: BPS
midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
Other Name: B GROUP

Detailed Description:

Previous studies have shown that propofol is superior to traditional sedation regimens with benzodiazepines plus opioids in ERCP procedures. Propofol is a potent hypnotic drug with a short duration of action and consequently a more rapid recovery time for the patients compared with the available Benzodiazepines. Several prospective studies have shown that balanced propofol sedation (BPS) can be used safely and effectively for diagnostic endoscopy under the direction of a gastroenterologist. BPS which was originally described by Cohen et al, combines small incremental doses of propofol with single induction doses of benzodiazepines and opioids under the direction of a physician that is not an anesthesiologist. Because BPS usually targets moderate sedation, adequate amnesia and analgesia can be achieved with concomitant administration of benzodiazepines and opioids. It may cause synergism between propofol and midazolam and reduce dose of propofol. However, there was no proven benefit between propofol alone titrated to moderate level of sedation and BPS; propofol titration combination with benzodiazepines and fentanyl.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • candidates for therapeutic ERCP

Exclusion Criteria:

  • patient age < 18 years
  • pregnant women
  • inability to provide informed consent
  • patients with total gastrectomy
  • American Society of Anesthesiologist (ASA) Class V patients
  • patients with known respiratory disease, patients with neurologic impairment
  • patients with known allergy to the drugs used, history of complications with previous sedation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01321047

Sponsors and Collaborators
Soon Chun Hyang University
Investigators
Study Chair: Tae Hoon Lee, MD Soonchunhyang University College of Medicine
  More Information

No publications provided

Responsible Party: Tae Hoon Lee, Soonchunhyang University College of Medicine, Cheonan Hospital
ClinicalTrials.gov Identifier: NCT01321047     History of Changes
Other Study ID Numbers: SCH-2011-18
Study First Received: March 22, 2011
Last Updated: March 22, 2011
Health Authority: Korea: Institutional Review Board

Keywords provided by Soon Chun Hyang University:
sedation
benzodiazepine
opioid
propofol

Additional relevant MeSH terms:
Propofol
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Hypnotics and Sedatives

ClinicalTrials.gov processed this record on July 20, 2014